Aignostics launches HETA Clinical. Where does OpenOnco fit?
Image analysis and cited pathway review solve different problems. The launch is real; claims of fewer failed tests still need clinical evidence.
Written retrospectively and published on October 18, 2026.
A company announcement is not independent evidence of clinical benefit. This comparison is informational, not medical advice. This article does not replace a doctor.
On 16 October, Aignostics announced four HETA Clinical tools for H&E whole-slide images: slide quality, tumor detection, mitotic count and tumor cellularity. It says these may help laboratories prioritize cases and avoid failed molecular tests. The release's 10–20% failure estimate comes from conversations with pathologists, not a published evaluation of these four tools. The product page says research use only, not for diagnostic procedures. A June HETA preprint evaluates cell classification, not whether these tools reduce failed tests or improve patient outcomes.
HETA analyzes tissue images; OpenOnco's free browser workflow organizes source-linked oncology rules and publishes code under the MIT license. OpenOnco cannot assess slides or count tumor cells. The checked Aignostics pages request a demo and list no routine price or public license for HETA Clinical. No head-to-head evidence shows either tool is more accurate. Image quality review and evidence review may complement each other. Sources and comparison checked 18 October 2026. This is background information, not a substitute for a qualified clinician.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.